Cancer, Breast cancer, Internal medicine, Cancer research and Oncology are her primary areas of study. Ana M. Gonzalez-Angulo combines subjects such as Pharmacology, Neovascularization and Pathology with her study of Cancer. Her work carried out in the field of Breast cancer brings together such families of science as Immunohistochemistry and Carcinoma.
Her studies deal with areas such as Endocrinology and Surgery as well as Internal medicine. Her research integrates issues of Mutation, PI3K/AKT/mTOR pathway, Signal transduction, Estrogen receptor and Kinase in her study of Cancer research. Her Oncology research integrates issues from Neoadjuvant therapy, Chemotherapy, Retrospective cohort study, Gynecology and Proportional hazards model.
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Cancer research. The Breast cancer study combines topics in areas such as Proportional hazards model, Surgery, Retrospective cohort study, Chemotherapy and Gynecology. Her Internal medicine study frequently links to related topics such as Pathology.
Her biological study spans a wide range of topics, including Neoadjuvant therapy, Survival rate, Inflammatory breast cancer, Disease and Cohort. She works mostly in the field of Cancer, limiting it down to topics relating to Bioinformatics and, in certain cases, Gene expression and Targeted therapy, as a part of the same area of interest. Her Cancer research research focuses on PI3K/AKT/mTOR pathway and how it relates to Protein kinase B, In vivo and Mutation.
Her primary scientific interests are in Breast cancer, Internal medicine, Oncology, Cancer and Cancer research. Her primary area of study in Breast cancer is in the field of Triple-negative breast cancer. Her Internal medicine study deals with Surgery intersecting with Multivariate analysis, Confidence interval and Everolimus.
Her Oncology research includes elements of Trastuzumab, Chemotherapy, Phases of clinical research, Triple Negative Breast Neoplasms and Hazard ratio. In the subject of general Cancer, her work in Neoadjuvant therapy is often linked to MK-2206, thereby combining diverse domains of study. Her studies in Cancer research integrate themes in fields like PTEN, Mutation, Signal transduction, Estrogen receptor and In vivo.
Ana M. Gonzalez-Angulo mainly investigates Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Her Breast cancer research is multidisciplinary, incorporating elements of Cancer research, Gynecology, Proportional hazards model and PTEN. She studied Internal medicine and Surgery that intersect with Multivariate analysis, Predictive value of tests and Recursive partitioning.
Her research in Oncology intersects with topics in Trastuzumab, Phases of clinical research, Clinical Oncology, Metastatic breast cancer and Prospective cohort study. Her Cancer research incorporates themes from Biopsy, Pathology, Surgical oncology and Bioinformatics. Her Triple-negative breast cancer research includes themes of Everolimus and Sirolimus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Katrien Berns;Hugo M. Horlings;Bryan T. Hennessy;Mandy Madiredjo.
Cancer Cell (2007)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Katherine Stemke-Hale;Ana Maria Gonzalez-Angulo;Ana Lluch;Richard M. Neve.
Cancer Research (2008)
Overview of Resistance to Systemic Therapy in Patients with Breast Cancer
Ana Maria Gonzalez-Angulo;Flavia Morales-Vasquez;Gabriel N. Hortobagyi.
Advances in Experimental Medicine and Biology (2007)
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Sao Jiralerspong;Shana L. Palla;Sharon Hermes Giordano;Funda Meric-Bernstam.
Journal of Clinical Oncology (2009)
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Bryan T. Hennessy;Ana Maria Gonzalez-Angulo;Katherine Stemke-Hale;Michael Z. Gilcrease.
Cancer Research (2009)
Targeting the mTOR Signaling Network for Cancer Therapy
Funda Meric-Bernstam;Ana Maria Gonzalez-Angulo.
Journal of Clinical Oncology (2009)
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
Hiroko Masuda;Keith A. Baggerly;Ying Wang;Ya Zhang.
Clinical Cancer Research (2013)
Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer
Deann P. Atchley;Constance T. Albarracin;Adriana Lopez;Vicente Valero.
Journal of Clinical Oncology (2008)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo;Kirsten M. Timms;Shuying Liu;Huiqin Chen.
Clinical Cancer Research (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: